Acumen and JCR Partner to Develop Enhanced Brain Delivery Alzheimer’s Therapy

Acumen Pharmaceuticals has entered into a strategic collaboration and licensing agreement with Japan-based JCR Pharmaceuticals to co-develop a next-generation Alzheimer’s disease treatment that combines Acumen’s amyloid beta oligomer (AβO)-targeting antibodies with JCR’s proprietary brain delivery technology.

The partnership focuses on developing an Enhanced Brain Delivery (EBD) therapy using JCR’s J-Brain Cargo platform, which enables biologic drugs to cross the blood-brain barrier—a major challenge in neurological drug development. The collaboration builds on over a year of feasibility work between the two companies and could lead to the creation of more effective and accessible treatments for Alzheimer’s disease.

Acumen’s CEO, Daniel O’Connell, called the agreement “an exciting next step” in advancing treatments for a disease with high unmet medical need. “By combining Acumen’s antibody technology with JCR’s validated BBB-penetrating system, we’re aiming to deliver more potent therapies directly to the brain,” he said. “We expect preclinical data in early 2026 to guide our development path.”

Acumen’s lead program, sabirnetug, is a monoclonal antibody currently in Phase 2 clinical trials (ALTITUDE-AD) across North America and Europe. The antibody has shown promising early results, including strong target engagement with toxic AβOs and reduction in amyloid plaques with a favorable safety profile.

JCR’s J-Brain Cargo platform uses transferrin receptor-mediated transport to deliver drugs to the central nervous system and has already supported an approved therapy in Japan for a lysosomal storage disorder. The collaboration may also explore additional AβO-specific antibodies in Acumen’s pipeline to expand potential treatment options.

Under the terms of the agreement, JCR receives an upfront payment and stands to earn additional milestone and royalty payments if Acumen exercises its option to develop up to two product candidates. A preclinical data package—including non-human primate studies—is expected in early 2026, at which point Acumen will determine whether to advance candidates to clinical development.

This partnership reinforces both companies’ shared goal of advancing next-generation neurological therapies by overcoming the key barrier of brain drug delivery.